MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.

Background: Primary chemotherapy has been tested as a possible approach for patients with high risk features but predicted clear mesorectal margins on preoperative MRI assessment. This study investigates the prognostic relevance of baseline and post-treatment MRI and pathology staging in rectal cancer patients undergoing primary chemotherapy. Patients and methods: Forty-six patients with T3 tumour > =2 mm from the mesorectal fascia were prospectively treated with Neoadjuvant Capecitabine, Oxaliplatin and Bevacizumab prior to surgery between 2009 and 2011. The baseline and post-treatment MRI: T, Nodal and Extra-mural venous invasion (EMVI) status were recorded as well as post-treatment MRI Tumour regression grade (TRG) and modified-RECIST assessment of tumour length. The post-treatment pathology (yp) assessments of T3 substage, N, EMVI and TRG status were also recorded. Three-year disease-free survival (DFS) and cumulative incidence of recurrence were estimated by using the Kaplan-Meier product-limit method, and Cox proportional hazards models were used to determine associations between staging and response on MRI and pathology with survival outcomes. Results: About 46 patients underwent neoadjuvant chemotherapy alone for high risk margin safe primary rectal cancer. The median follow-up was 41 months, 5 patients died and 11 patients experienced relapse (2 local, 8 distant and 1 both). In total 23/46 patients were identified with MRI features of EMVI at baseline. mrEMVI positive status carried independent prognostic significance for DFS (P = 0.0097) with a hazard ratio of 31.33 (95% CI: 2.3-425.4). The histopathologic factor that was of independent prognostic importance was a final ypT downstage of ypT3a or less, hazard ratio: 14.0 (95% CI: 1.5-132.5). Conclusions: mrEMVI is an independent prognostic factor at baseline for poor outcomes in rectal cancer treated with neoadjuvant chemotherapy while ≤ypT3a is associated with an improvement in DFS. Future preoperative therapy evaluation in rectal cancer patients will need to stratify treatment according to baseline EMVI status as a crucial risk factor for recurrence in patients with predicted CRM clear rectal cancer.

Technology versus humanism: how patients perceive the use of electronic health records in physicians' offices--a qualitative study.

Electronic Health Records (EHRs) have the potential to improve the quality of care. In view of the accelerated adoption of EHRs, there is a need to understand conditions necessary for their effective use. Patients are the focus of healthcare and their perceptions and expectations need to be included in developing and implementing EHRs. The purpose of this study was to gather exploratory qualitative information from patients about their experiences and perceptions regarding the effects of EHRs on healthcare quality in physicians' offices. We conducted five focus groups with patients representing a random mix of diverse socio-demographic backgrounds in Oklahoma. Related to EHRs, patients reported improvements on the technical side of care but no change on the human side. They expressed concerns about the potential for breach of confidentiality and security of medical records. They were also concerned about the possibility of governmental agencies or insurance companies having unauthorized access to patient records. Patients differentiated between the human and technical sides of care and reported no change or improvement in the doctor-patient interaction. Patients have an important perspective on the use of EHRs and their perceptions and experiences should be considered in the development, adoption and implementation of EHRs. Otherwise, the use of EHRs may not be fully effective. There is also a need to educate patients about the potential benefits and risks of EHRs and the steps being taken to mitigate such risks.

Chemical characterization and antioxidant capacity of the araçá-pera (Psidium acutangulum): An exotic Amazon fruit.

The "araçá-pera" (Psidium acutangulum DC) is an exotic guava consumed by the Brazilian Amazon population. This paper describes 22 compounds from this fruit by UHPLC-HRMS and NMR methods, being one disaccharide, five monosaccharides, two organic acids, one trihydroxycinnamic acid glucopyranosyl, one tannine digalloyl glucopyranosyl, five triterpenoid acids, and six fatty acids. It also quantifies the level of ascorbic acid (AA) by HPLC-MS (74.32±1.23mg/100g of fresh fruit), and defines the chemical antioxidant activities by DPPH and ABTS+ assays (24.96±0.75, 90.57±0.63mg of vitamin C/100g fresh fruit, respectively), and a cell-based assays (76-100%). These results have shown that this exotic guava can be consumed as a nutraceutical ingredient, as well as be used in the production of functional foods in the Amazonian diet to prevent chronic and oxidative diseases.

Association of SLC11A1 with tuberculosis and interactions with NOS2A and TLR2 in African-Americans and Caucasians.

SETTING: Host defense factors may influence the development of active tuberculosis (TB). OBJECTIVE: To test variants in solute carrier family 11A, member 1 (SLC11A1), for an association with TB. METHODS: A mixed case-control study of TB cases, relatives or close contact controls, consisting of 474 African-Americans (243 families) and 381 Caucasians (192 families), examined 13 SLC11A1 polymorphisms for association with pulmonary TB using generalized estimating equations adjusting for age and sex. RESULTS: Two associations were observed in Caucasians (rs3731863, P = 0.03, and rs17221959, P = 0.04) and one in African-Americans (rs3731865, P = 0.05). Multilocus analyses between polymorphisms in SLC11A1 and 11 TB candidate genes detected interactions between SLC11A1 and inducible nitric oxide synthase (NOS2A) in Caucasians (rs3731863 [SLC11A1] x rs8073782 [NOS2A], P = 0.009; rs3731863 [SLC11A1] x rs17722851 [NOS2A], P = 0.007) and toll-like receptor 2 (TLR2) in African-Americans (rs3731865 [SLC11A1] x rs1816702, P = 0.005). CONCLUSIONS: No association was detected with 5'(GT)(n) promoter polymorphism previously associated with lower SLC11A1 expression, rs17235409 (D543N), or rs17235416 (3' TGTG insertion/deletion polymorphism). SLC11A1 polymorphism rs3731865 was associated with TB in African-Americans, consistent with previous findings in West Africans. These results suggest that variants in SLC11A1 increase susceptibility to pulmonary TB and interact with other variants that differ by race.

Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience

INTRODUCTION: Neoadjuvant 5-FU-based chemoradiotherapy in resectable rectal cancer (RC) is a standard of treatment. The use of oral fluoropyrimidines and new agents such as oxaliplatin may improve efficacy and tolerance. MATERIAL AND METHODS: Between 1999 and 2009, 126 RC patients with T3-T4 and/or N+ disease were given three successive protocols: UFT (32), UFT-oxaliplatin (75) and capecitabine-oxaliplatin (19), alongside 45 Gy of radiotherapy; with surgery 4-6 weeks after. Adjuvant treatment was given in all patients. The primary objective was pathologic complete response (pCR). RESULTS: Preoperative therapy was well tolerated, with no toxic deaths and a 15% grade 3-4 toxicity rate. Eighty-five percent of patients received the full chemotherapy dose, 56% had an abdominoperineal resection, 6% reinterventions and 57% received the full adjuvant chemotherapy planned. The pCR rate was 13%. The downstaging rate was 80%; 8% had progression of disease. The relapse rate was 20%, with local relapse in 6%. By 5 years of followup, 92% of relapses had occurred. Median follow-up was 73 months, 5- and 10-year disease-free survival rates were 75% and 50%, and 5- and 10-year overall survival rates were 79% and 66% respectively. There was no benefit from the use of oxaliplatin regarding survival or pCR rates. Older patients had worse long-term outcomes. CONCLUSIONS: Neoadjuvant chemoradiotherapy with oral fluoropyrimidines and oxaliplatin is feasible and well tolerated. The risk of early progression is low. However, there was no added benefit with the use of oxaliplatin. There were no relapses in patients with pCR. The role of adjuvant chemotherapy is unclear (AU)

Tratamiento adyuvante con 5-fluorouracilo y levamisol o radioterapia en pacientes con cáncer colorrectal resecado en estadios II y III / Combinations of 5-fluorouracil with levamisole or radiotherapy adjuvant therapy in patients with stages II and III resected colorectal cancer

Propósito: Las primeras pautas eficaces de tratamiento adyuvante para el cáncer colorrectal fueron las combinaciones de 5-fluorouracilo con levamisol (5FU+lev, en el cáncer de colon) y con radioterapia (5FU+RT, en el cáncer de recto). Ambas se emplearon en nuestro centro entre 1992 y 1997. Presentamos aquí sus resultados a largo plazo en términos de toxicidad y supervivencia. Material y métodos: Setenta y cinco pacientes con cáncer de colon (48) y recto (27) resecado con intención curativa en estadios II (36 por ciento) y III (64 por ciento) recibieron quimioterapia basada en la administración de 5FU en bolo (5FU+lev o 5FU+RT en función de la localización primaria). Cincuenta y cinco enfermos (73 por ciento) completaron el tratamiento previsto de un año. La mediana de intensidad de dosis fue del 96 por ciento. La toxicidad fue leve y aceptable, principalmente en forma de diarrea y vómitos. Resultados: Con una mediana de seguimiento de 48 meses (extremos, 29-102), 27 pacientes (36 por ciento) han recaído. La supervivencia global a los 5 años fue de 93 por ciento y 67 por ciento para los enfermos con cáncer de colon en estadios II y III, y de 91 por ciento y 47 por ciento para los pacientes con cáncer de recto en estadios II y III, respectivamente. De los factores pronóstico analizados, sólo la estadificación postquirúrgica (pTNM) se relacionó significativamente con la evolución de los pacientes, mientras que la localización no alcanzó significación estadística. Conclusiones: 5FU+lev y 5FU+RT son tratamientos adyuvantes bien tolerados en el cáncer colorrectal resecado. Sin embargo, el seguimiento a largo plazo refleja la necesidad de mejorar sus resultados, especialmente en aquellos pacientes con estadio III y con tumores primarios rectales (AU)

Tratamiento del cáncer colorrectal: encuesta de la Sociedad Valenciana de Cirugía / Management of colorectal cancer: a survey by the Surgical Society of Valencia

Introducción. Motivados por conocer la situación actual del tratamiento del cáncer colorrectal en los hospitales de la Comunidad Valenciana, y por encargo de la Sociedad Valenciana de Cirugía, se elaboró una encuesta dirigida a todos los Servicios de Cirugía General y Aparato Digestivo de estos centros, cuyo resultado exponemos. Material y método. Se realizó un análisis retrospectivo mediante encuesta, y se obtuvieron los datos desde el año 1997 hacia atrás, agrupándolos por años naturales. La encuesta abordó siete apartados del tratamiento del cáncer colorrectal (diagnóstico, cirugía programada, cirugía de urgencias, terapéutica adyuvante, enfermedad avanzada, seguimiento y anatomía patológica), y se estudiaron tanto parámetros de estructura como de proceso, así como los resultados de los mismos. Resultados. Se remitieron un total de 20 cuestionarios obteniéndose 17 respuestas (85 por ciento). Sólo 2 hospitales (11,7 por ciento) disponen de ecografía endorrectal. Ninguno realiza por sistema enema de doble contraste. Únicamente en 3 hospitales (17,64 por ciento), el cáncer rectal es tratado por un grupo determinado de cirujanos. Cinco hospitales (29,4 por ciento) realizan con asiduidad el lavado colónico intraoperatorio en la cirugía del cáncer obstructivo. Siete centros (41,1 por ciento) llevan a cabo algún tipo de terapéutica adyuvante preoperatoria en el cáncer rectal, siendo la cifra total de recidivas locales del 11,58 por ciento a los 2 años de seguimiento. No existe ningún protocolo establecido de seguimiento postoperatorio de estos pacientes en 3 hospitales (17,64 por ciento). El número medio de ganglios aislados por pieza quirúrgica es de nueve, y sólo 2 centros (11,7 por ciento) reflejan en sus informes anatomopatológicos la afectación del margen circunferencial. Conclusiones. De los resultados obtenidos en esta encuesta y su posterior comparación con la bibliografía concluimos: a) en el aspecto diagnóstico, se debe mejorar el porcentaje de colonoscopias completas; los enemas opacos, cuando se realicen, deberían llevarse a cabo sistemáticamente mediante la técnica de doble contraste; sería aconsejable implantar la ecografía endorrectal como exploración de rutina para la correcta estadificación del cáncer rectal con el fin de realizar una correcta selección de los pacientes candidatos a terapéutica adyuvante preoperatoria; b) en la cirugía electiva, dado que la cirugía del cáncer rectal depende del cirujano, creemos que debería ser realizada por personal especialmente entrenado; c) respecto a la cirugía del cáncer colorrectal obstructivo, si las condiciones del paciente lo permiten, debería tratarse de aumentar el porcentaje de resecciones con anastomosis primaria, entrenando al equipo quirúrgico en la realización del lavado intraoperatorio; d) se necesitan estudios prospectivos para valorar el régimen terapéutico adyuvante preoperatorio más adecuado; e) es recomendable que los distintos hospitales dispongan de protocolos de seguimiento postoperatorio homogéneos, con la finalidad de uniformizar el control de estos pacientes, además de prestarles un apoyo psicológico y servir de auditoría de sus propios resultados, y f) debe tratarse de que en los informes anatomopatológicos se especifique el margen circunferencial, así como intensificar el aislamiento de ganglios linfáticos a fin de evitar la infraestadificación tumoral (AU)